Related Experiment Video
Updated: Jun 29, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Targeting angiogenesis in the treatment of lung cancer
Paul Wheatley-Price1, Frances A Shepherd
1University Health Network, Princess Margaret Hospital Division and the University of Toronto, Toronto, Ontario, Canada.
Abstract:
Inhibition of angiogenesis now plays a central role in the management of many malignancies. Angiogenesis plays an important role in lung cancer and increasing numbers of antiangiogenesis agents are being investigated in all types of pulmonary malignancies. The monoclonal antibody, bevacizumab, has demonstrated efficacy (improved response rates and overall survival) in phase II and III trials in combination with standard first-line chemotherapy in non-small cell lung cancer. However patients in the large phase III studies were highly selected to reduce the risk of fatal hemoptysis. Many small molecule tyrosine kinase inhibitors, particularly sorafenib, sunitinib, vandetanib, and cediranib, are currently being investigated in phase III trials as monotherapy or in combination with standard therapy. Alternative antiangiogenesis approaches such as vascular endothelial growth factor-trap and anticoagulation are also being investigated. Targeting angiogenesis is an exciting and attractive area in the treatment of lung cancer, and the results of ongoing trials are eagerly awaited. More work is required to identify subgroups of patients most likely to benefit from these drugs.
Insights
Antiangiogenesis therapies are crucial for managing lung cancer, with agents like bevacizumab showing promise. Further research is needed to identify patient subgroups who will benefit most from these novel treatments.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Angiogenesis is a key process in tumor growth and is a primary target for cancer therapies.
- Antiangiogenesis agents are increasingly investigated for various pulmonary malignancies.
Purpose of the Study:
- To review the role of antiangiogenesis strategies in lung cancer management.
- To discuss the efficacy and ongoing investigations of various antiangiogenesis agents in lung cancer.
Main Methods:
- Review of phase II and III clinical trials involving antiangiogenesis agents.
- Discussion of different therapeutic approaches including monoclonal antibodies, tyrosine kinase inhibitors, and other strategies.
Main Results:
- Bevacizumab demonstrated efficacy in non-small cell lung cancer when combined with chemotherapy.
- Several small molecule tyrosine kinase inhibitors are under investigation in phase III trials.
- Alternative approaches like VEGF-trap and anticoagulation are also being explored.
Conclusions:
- Targeting angiogenesis is a promising strategy in lung cancer treatment.
- Ongoing trials are eagerly anticipated, but further research is required to identify patient subgroups likely to benefit.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...